The Parkinson's Disease Market Size in the 7MM was ~USD 3,539 Million in 2025, and is projected to rise with a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Parkinson Disease Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Parkinson Disease, historical and forecasted epidemiology as well as Parkinson Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore Parkinson Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Parkinson Disease Market Report
• On December 18, 2025- UCB Biopharma SRL announced a Phase 2 study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
• On December 12, 2025- Biohaven Therapeutics Ltd initiated A Phase 2/3 study Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease.
• On December 12, 2025- Prevail Therapeutics conducted a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.
• According to DelveInsight's epidemiology model, the total diagnosed prevalent cases of Parkinson's disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the forecast period (2024-2034) due to increasing awareness, aging population, and advancement of diagnostic procedures.
• In the 7MM, Japan accounted for approximately 258 thousand cases diagnosed prevalent cases of Parkinson's disease in 2023.
• Among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Parkinson's disease with nearly 495 thousand cases in 2023 followed by France accounting for approximately 277 thousand cases. On the other hand, Spain accounted for the least with nearly 149 thousand cases.
• In 2023, Japan accounted for approximately 135 thousand cases in males and 123 thousand cases in females, based on gender-specific diagnosed prevalent cases of Parkinson's disease. These cases are expected to increase during the forecast period.
• In the US, nearly 19 thousand cases were diagnosed with Parkinson's disease in the age group =49 years, 215 thousand cases in 50-64 years, 449 thousand cases in 65-74 years, and 527 thousand cases in =75 years in 2023.
• Among the stage-specific diagnosed prevalent cases of Parkinson's disease in Japan, there were approximately 9 thousand cases for Stage I, 40 thousand cases for Stage II, 107 thousand cases for Stage III, 70 thousand cases for Stage IV, and 31 thousand cases for Stage V in 2023.
• In Japan, there were approximately 73 thousand cases of psychosis associated with Parkinson's disease in 2023.
• In the assessment done by DelveInsight, the estimated Diagnosed Prevalent Cases of Mild Cognitive Impairment due to Parkinson's Disease in the US were nearly 508 thousand in 2023
• The leading Parkinson Disease Companies such as UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics LLC and others.
• Promising Parkinson Disease Therapies such as VTX3232, Rasagiline, Safinamide Methanesulfonate, Levetiracetam, CTC-413, CVXL-0107, Levodopa, and others.

Strategize your business goals by understanding market dynamics @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson Disease Overview
Parkinson disease is a chronic, progressive neurodegenerative disorder that primarily affects movement due to the gradual loss of dopamine-producing neurons in the substantia nigra region of the brain, leading to impaired motor control and coordination. It is characterized by hallmark motor symptoms such as resting tremor, bradykinesia (slowness of movement), muscular rigidity, and postural instability, along with a wide range of non-motor symptoms including cognitive decline, depression, sleep disturbances, autonomic dysfunction, and sensory abnormalities, which often precede motor manifestations.

Parkinson Disease Epidemiology Segmentation in the 7MM
• Total Parkinson's Disease Diagnosed Prevalent Cases
• Parkinson's Disease Age-specific Diagnosed Prevalent Cases
• Parkinson's Disease Stage-specific Diagnosed Prevalent Cases
• Parkinson's Disease Gender-specific Diagnosed Prevalent Cases

Visit for more about Parkinson Disease Prevalence @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Parkinson Disease Therapies

• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals
CREXONT is a novel oral formulation of carbidopa/levodopa (CD/LD) that combines immediate-release (IR) granules and extended-release (ER) pellets. This prescription medication is used to treat Parkinson's disease, Parkinson's disease caused by brain infection or inflammation, and Parkinson's disease-like symptoms resulting from carbon monoxide or manganese poisoning in adults. The ER beads in CREXONT consist of levodopa (LD), coated with a sustained-release polymer for slow drug release, a mucoadhesive polymer to ensure the granules remain at the absorption site longer, and an enteric coating to prevent premature disintegration in the stomach. This formulation is distinct from RYTARY (carbidopa/levodopa) extended-release capsules, Amneal's extended-release CD/LD treatment for Parkinson's disease approved by the US FDA in 2015.

• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie
PRODUODOPA is the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating severe motor fluctuations in advanced Parkinson's disease patients whose symptoms are inadequately controlled by other therapies. The continuous delivery of PRODUODOPA provides levodopa 24 hours a day, potentially extending the period of well-controlled symptoms, often referred to as "On" time. AbbVie received marketing authorization for PRODUODOPA through the decentralized procedure in the third quarter of 2022.

• XADAGO/EQUFINA (safinamide): Newron Pharmaceuticals/ Zambon/ Supernus Pharmaceuticals/ Eisai
XADAGO is an inhibitor of monoamine oxidase B (MAO-B) indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. The precise mechanism by which XADAGO exerts its effect on Parkinson's disease is unknown. However, it is believed that by inhibiting MAO-B activity and blocking the catabolism of dopamine, there is an increase in dopamine levels and subsequent dopaminergic activity in the brain. XADAGO tablets contain safinamide as the mesylate salt and are available as 50 mg and 100 mg film-coated tablets for oral administration. Each tablet contains 65.88 mg or 131.76 mg of safinamide mesylate, equivalent to 50 mg or 100 mg of the safinamide-free base, respectively. The drug is approved under the brand name XADAGO in the US and Europe and as EQUFINA in Japan.

Emerging Parkinson Disease Therapies
• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals
SPN-830 (apomorphine infusion device) is an investigational apomorphine infusion device under review for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease patients that are not adequately controlled with oral levodopa and one or more adjunct Parkinson's disease medications. SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion pump under the skin for 14-18 h. The target infusion rate ranged between 3 mg and 8 mg per h. The thin, small needle applied underneath the skin is usually placed on the abdomen or upper thigh. Such administration has the potential to be less invasive, with fewer injection sites, and is more convenient than Supernus Pharmaceutical's already approved product APOKYN, which mimics the action of dopamine in the brain, is intended to reduce off periods on demand, and is administered under the skin.

• Tavapadon: AbbVie (Cerevel Therapeutics)
Cerevel Therapeutics is developing tavapadon FDA approval to treat both early and late-stage Parkinson's disease. Tavapadon FDA approval was rationally designed as an orally bioavailable, once-daily partial agonist that selectively targets dopamine D1 receptor and dopamine D5 receptor subtypes to balance meaningful motor activity with a favourable safety profile. Tavapadon FDA approval differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation or somnolence, compromised impulse control, and risk of psychotic symptoms, including hallucinations. The Parkinson's disease drug is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor over excitation and desensitization caused by full agonists, leading to dyskinesia and exacerbation of "off" time. It has the potential to be used as both a monotherapy for early-stage Parkinson's disease and as adjunctive therapy for late-stage Parkinson's disease.

• P2B001 (extended-release pramipexole and rasagiline): Pharma Two B
P2B001, being developed by Pharma Two B, is a novel, once-daily combination of extended-release pramipexole, a low-dose dopamine agonist, and rasagiline, a low-dose MAO-B inhibitor for the treatment of Parkinson's disease. Pramipexole mimics the effects of dopamine while minimizing the breakdown of dopamine. The two drugs work in two different mechanisms that help each other, which gives combined activity better than each drug. Lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs in an improved formulation that is hoped to be more effective in controlling Parkinson's disease symptoms and with fewer side effects than each of the drugs taken alone or the currently available commercial drugs taken together.

Parkinson's Disease Treatment Market
The Parkinson's disease treatment market landscape faces significant unmet needs, particularly for curative and disease-modifying therapies. Better motor symptom control, especially for tremors, gait, balance, and psychosis treatment, remains a critical challenge. Nevertheless, a plethora of medications is under development. These include drugs that specifically target a-synuclein pathology, widely considered to be the driver of neurodegeneration in Parkinson's disease. These drugs offer hope for disease-modifying agents in the short- to medium-term future. In combination with several regenerative approaches, including stem cells and gene therapies, therapeutics for Parkinson's disease are likely to see significant advances over the coming years, with several novel, effective options likely to become available in the foreseeable future.

For more information, visit Parkinson Disease Medication and Companies @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson Disease Market Outlook
Parkinson's disease is a progressively worsening neurodegenerative disorder with an unclear cause and pathogenesis. Its global burden is increasing, driven by aging populations and environmental factors. Classic Parkinson's disease symptoms include motor issues like bradykinesia, rigidity, tremors, and postural instability, along with non-motor symptoms such as depression, cognitive impairment, and autonomic disturbances, which significantly affect quality of life. Diagnosing Parkinson's is challenging due to symptom overlap with other movement disorders, with imaging like PET scans aiding in diagnosis. While no curative therapy exists, various pharmacological and non-pharmacological treatments are used to manage symptoms. Carbidopa/levodopa remains the most effective treatment, with new formulations like CREXONT (approved in August 2024) and RYTARY (approved in 2015) offering symptom relief. DUOPA, a carbidopa/levodopa enteral suspension, and HARUROPI TAPE (ropinirole HCL), a transdermal patch, provide additional options, though innovations have been limited.

Parkinson Disease Companies
UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics LLC and others.

Scope of the Parkinson Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Parkinson Disease Companies- UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics LLC and others.
• Parkinson Disease Therapies- VTX3232, Rasagiline, Safinamide Methanesulfonate, Levetiracetam, CTC-413, CVXL-0107, Levodopa, and others.
• Parkinson Disease Therapeutic Assessment: Parkinson Disease current marketed and Parkinson Disease emerging therapies
• Parkinson Disease Market Dynamics: Parkinson Disease market drivers and Parkinson Disease market barriers
• Parkinson Disease Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson Disease Unmet Needs, KOL's views, Analyst's views, Parkinson Disease Market Access and Reimbursement

Do you know the treatment paradigms for different countries? Download our Parkinson Disease Treatment Market @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Parkinson Disease Market Report Introduction
3. Executive Summary
4. Parkinson Disease Market Overview at a Glance
5. Key Parkinson Disease Events
6. Parkinson Disease Epidemiology and Market Methodology
7. Parkinson Disease Background and Overview
8. Parkinson Disease Treatment and Management
9. Parkinson Disease Epidemiology and Patient Population
10. Parkinson Disease Patient Journey
11. Parkinson Disease Marketed Drugs
12. Parkinson Disease Discontinued Product
13. Parkinson Disease Emerging Drugs
14. Parkinson Disease: Seven Major Market Analysis
15. Parkinson Disease Unmet Needs
16. Parkinson Disease SWOT Analysis
17. Parkinson Disease KOL Views
18. Parkinson Disease Market Access and Reimbursement
19. Appendix
20. Delveinsight Capabilities
21. Disclaimer
22. About Delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.